Werewolf Therapeutics
HOWL
48 hedge funds and large institutions have $11.7M invested in Werewolf Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 12 closing their positions.
25% more capital invested
Capital invested by funds: $9.34M → $11.7M (+$2.32M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.51% less ownership
Funds ownership: 30.36% → 28.84% (-1.5%)
6% less funds holding
Funds holding: 51 → 48 (-3)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$386K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.9K |
| 4 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$20.4K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$324K |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$127K |
| 3 |
Renaissance Technologies
New York
|
-$111K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$102K |
| 5 |
Millennium Management
New York
|
-$74K |
HOWL Hedge Fund Activity: Q1 2026 in Review
48 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q1 2026, worth a combined $11.7M — up 25% from $9.34M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HOWL and 10 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Squadron Capital Management, opening a new position worth an estimated $386K. The largest seller was Bank of America, cutting an estimated $324K.
- 48 institutional investors held Werewolf Therapeutics (HOWL) as of Q1 2026, down from 51 in Q4 2025.
- Funds reported $11.7M of Werewolf Therapeutics stock for Q1 2026, up 25% quarter-over-quarter.
- 10 funds opened new Werewolf Therapeutics positions in Q1 2026 and 12 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q1 2026 was Squadron Capital Management, an estimated $386K added.
- The largest Werewolf Therapeutics seller in Q1 2026 was Bank of America, an estimated $324K sold.
Based on aggregated 13F filings for Q1 2026.